Sugi Predict

Sugi Predict / Compounds / SCHEMBL4592755

SCHEMBL4592755

SCHEMBL4592755

Fc1ccc(N2N=C(c3ccccc3)CC2c2ccncc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 8/20 0.67
▸ KMT2A Q03164 8/20 0.67
▸ GAA P10253 7/20 0.67
▸ KDM4E B2RXH2 7/20 0.67
▸ ALDH1A1 P00352 7/20 0.67
▸ GLA P06280 6/20 0.67
▸ MAPT P10636 5/20 0.67
▸ ATM Q13315 4/20 0.67
▸ L3MBTL1 Q9Y468 4/20 0.67
▸ LMNA P02545 4/20 0.67
▸ HPGD P15428 2/20 0.67
▸ HSP90AA1 P07900 1/20 0.67
▸ CA1 P00915 2/20 0.63
▸ CA2 P00918 2/20 0.63
▸ NR3C2 P08235 2/20 0.62
▸ SMN1; SMN2 Q16637 3/20 0.62
▸ TDP1 Q9NUW8 3/20 0.62
▸ MAPK1 P28482 2/20 0.62
▸ RXFP1 Q9HBX9 1/20 0.62
▸ EGFR P00533 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4594248 0.90 MEN1 (0.58) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL4254323 0.86 MEN1 (0.87) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL31429937 0.86 MEN1 (0.82) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL4593362 0.84 GAA (0.54) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL23052404 0.81 MEN1 (0.73) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL395608 0.81 MEN1 (0.73) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL13680425 0.81 EGFR (0.75) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL27955194 0.80 MEN1 (1.00) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL13680429 0.78 EGFR (0.71) MEN1KMT2AGAAKDM4EALDH1A1
SCHEMBL10361833 0.78 MEN1 (0.69) MEN1KMT2AGAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030153569-A1 Novel pyrazole and pyrazoline substituted compounds SMITHKLINE BEECHAM CORPORATION 2003-08-14 — — US claimed
US-20020156104-A1 CSBP/p38/RK kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2002-10-24 — — US claimed
EP-1023066-A4 NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2001-05-23 — — EP claimed
EP-1023066-A1 NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2000-08-02 — — EP claimed
WO-1998056377-A1 NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 1998-12-17 — — WO claimed
EP-1539121-A4 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC (US) 2008-08-13 — — EP disclosed
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS PROTTER ANDREW A 2008-05-08 — — US disclosed
EP-1583535-A4 METHODS FOR TREATING DIABETES SCIOS INC (US) 2008-03-19 — — EP disclosed
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase PROTTER ANDREW A 2008-02-14 — — US disclosed
US-7268139-B2 Methods of promoting osteogenesis SCIOS, INC. (US) 2007-09-11 — — US disclosed
US-7244441-B2 Stents and intra-luminal prostheses containing map kinase inhibitors SCIOS, INC. (US) 2007-07-17 — — US disclosed
EP-1676574-A2 Methods for promoting survival of transplanted tissues and cells Johnson & Johnson Vision Care, Inc. (US) 2006-07-05 — — EP disclosed
WO-2005032551-A1 TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE SCIOS INC. (US) 2005-04-14 — — WO disclosed
US-20040171659-A1 Methods for treating diabetes SCIOS, INC. 2004-09-02 — — US disclosed
US-20040162289-A1 Methods of promoting osteogenesis UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY 2004-08-19 — — US disclosed
US-6774127-B2 TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION 2004-08-10 — — US disclosed
WO-2004019873-A9 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC (US) 2004-06-24 — — WO disclosed
WO-2004053107-A2 METHODS FOR TREATING DIABETES SCIOS INC. (US) 2004-06-24 — — WO disclosed
WO-2004019873-A2 METHODS OF PROMOTING OSTEOGENESIS SCIOS INC. (US) 2004-03-11 — — WO disclosed
US-20020156104-A1 CSBP/p38/RK kinase inhibitors SMITHKLINE BEECHAM CORPORATION 2002-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108658-A1 METHODS OF PROMOTING OSTEOGENESIS MAPK1, BMP2, MAPK3 MEN1 1366/4885KMT2A 2643/4885GAA 1425/4885
US-20040162289-A1 Methods of promoting osteogenesis MAPK1, BMP2, MAPK3 MEN1 1366/4885KMT2A 2643/4885GAA 1425/4885
US-20030153569-A1 Novel pyrazole and pyrazoline substituted compounds PDXK, COQ8A, PDK3 MEN1 3265/4885KMT2A 3711/4885GAA 3284/4885
US-20080039461-A1 Treatment of pain by inhibition of p38 map kinase OPRK1, OPRL1, MAPK3 MEN1 4518/4885KMT2A 4237/4885GAA 4058/4885
US-20040171659-A1 Methods for treating diabetes SLC5A2, MAPK4, MAPK3 MEN1 4158/4885KMT2A 3019/4885GAA 1011/4885
US-20020156104-A1 CSBP/p38/RK kinase inhibitors MAPKAPK2, MAPKAPK3, MAPKAPK5 MEN1 4619/4885KMT2A 3249/4885GAA 4787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.